<DOC>
	<DOCNO>NCT00263575</DOCNO>
	<brief_summary>The purpose study evaluate long-term safety effectiveness EN3267 treat breakthrough pain episode opioid cancer patient use stable dos opioid medication .</brief_summary>
	<brief_title>Long-term Safety Study Sublingual Fentanyl Tablets Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Breakthrough Pain</mesh_term>
	<mesh_term>Fentanyl</mesh_term>
	<criteria>Males females 17 year age old . Stable cancerrelated pain . Are receive stable , fixedschedule oral opioid regimen equivalent 60 1000 mg oral morphine per day transdermal fentanyl therapy equivalent 50 300 Âµg/h , stable dose opioid medication relief breakthrough pain . Experiencing 14 episode breakthrough pain per day . Meet criterion define Eastern Cooperative Oncology Group ( ECOG ) Performance Status Grade 0 , 1 , 2 . Have previously expose EN3267 . Are pregnant lactating . Have uncontrolled rapidly escalate pain . Have clinically significant condition would , investigator 's opinion , preclude participation study compromise data collection . These condition may include cardiopulmonary disease , and/or neurologic/psychologic condition . Are scheduled take MAOIs ( monoamine oxidase inhibitor ) study . Are scheduled receive antineoplastic therapy , investigator 's opinion , influence assessment breakthrough pain . Are scheduled receive investigational drug EN3267 course study . Have hypersensitivity , allergy contraindication fentanyl . Have significant prior history substance abuse alcohol abuse . Would difficulty comply protocol , assess investigator . Are unable read , write , comprehend English language order complete diary .</criteria>
	<gender>All</gender>
	<minimum_age>17 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>EN3267</keyword>
	<keyword>Breakthrough Pain</keyword>
	<keyword>Safety Study</keyword>
	<keyword>Fentanyl Tablets</keyword>
</DOC>